Skip to main content

Women and HIV: Antiretroviral Use for Pregnancy among Women with HIV

AAHIVM Course Banner
0.75 CEUs
Women and HIV:
Antiretroviral Use for Pregnancy Among Women with HIV

Module Description Both the prevention and treatment of HIV in women present various challenges that differ from their male counterparts. Antiretroviral use impacts the female reproductive system, including the use of hormonal contraception, pregnancy and breastfeeding, and pharmacokinetics and pharmacodynamics in women. Women also experience unique and different adverse events affecting gynecological, cardiovascular, and neurological systems. Treating pregnant women for HIV-1 infection must balance overall efficacy and the safety of both the pregnant woman and the fetus.

Credit Dates 01/10/2023 – 01/09/2024

Jointly provided by Postgraduate Institute for Medicine and the American Academy of HIV Medicine.

This activity is supported by independent medical education grants from Gilead Sciences, Inc., Merck & Co. and ViiV Healthcare. 
Learning Objectives
  • Appraise advances in ART for the prevention of perinatal HIV transmission
  • Detail the recommended ART regimens for pregnant women
  • Apply knowledge of physiologic changes in pregnancy to provide optimal management for pregnant women living with HIV
  • Appreciate how data on ARV agents during pregnancy are gathered and their significance
  • Discuss the safety of ARV agents during pregnancy

Target Audience
This activity is intended for physicians, physician assistants, nurse practitioners, registered nurses and pharmacists who are engaged in the care of female patients with or at risk for HIV.

William R. Short, MD, MPH, FIDSA
Associate Professor, Medicine
Perelman School of Medicine
University of Pennsylvania, Philadelphia, PA

Method of Participation and Request for Credit
There are no fees for participating and receiving CME/CE credit for this activity.

During the period January 10, 2023 through January 9, 2024, participants must read the learning objectives and faculty disclosures and study the educational activity.

If you wish to receive acknowledgment for completing this activity, please complete the post-test and evaluation on On the navigation menu, click on “Find Post-test/Evaluation by Course” and search by course ID 17177. Upon registering and successfully completing the post-test with a score of 75% or better and the activity evaluation, your certificate will be made available immediately.

For Pharmacists: Upon successfully completing the post-test with a score of 75% or better and the activity evaluation form, transcript information will be sent to the NABP CPE Monitor Service within four weeks.

If you have questions regarding the certification of this activity, please contact PIM via email at or visit

If you have questions regarding the certification of this activity, please contact PIM via email at or visit In support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine and the American Academy of HIV Medicine. Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician Continuing Education Credit The Postgraduate Institute for Medicine designates this internet activity for a maximum of 0.75 AMA PRA Category 1 Credit(s). Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Continuing Pharmacy Education The Postgraduate Institute for Medicine designates this continuing education activity for 0.75 contact hours (0.075 CEUs) of Accreditation Council for Pharmacy Education (Universal Activity #JA4008162-9999-23-077-H02-P). Type of Credit: Knowledge

Continuing Nursing Education The maximum number of hours awarded for this Continuing Nursing Education activity is 0.75 contact hours, 0.3 pharmacotherapy hours for APRN.

Disclosure of Conflict of Interest
Postgraduate Institute for Medicine (PIM) requires faculty, planners, and others in control of educational content to disclose all their financial relationships with ineligible companies. All identified conflicts of interest (COI) are thoroughly vetted and mitigated according to PIM policy. PIM is committed to providing its learners with high quality accredited continuing education activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.

Dr. Short receives consultation fees (i.e. Advisory Board) from ViiV Healthcare and grant support from Gilead Sciences. 

Planners and Managers
The PIM planners and managers have nothing to disclose. The Academy managers have nothing to disclose.

Media: Internet

Computer System Requirements: This program requires the use of an internet-connected computer or device and a modern web browser capable of streaming video.

Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient's conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer's product information, and comparison with recommendations of other authorities.